Alteration in protein expression in estrogen receptor alpha-negative human breast cancer tissues indicates a malignant and metastatic phenotype

Clinical and Experimental Metastasis

Volumn 27, Issue 7, 2010, Pages 493-503

  Sahab, Ziad J ^a,d   Man, Yan Gao ^b,c   Semaan, Suzan M ^a   Newcomer, Robert G ^a   Byers, Stephen W ^d   Sang, Qing Xiang Amy ^a  

^a FLORIDA STATE UNIVERSITY   (United States)

^b ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^c JILIN UNIVERSITY   (China)

^d GEORGETOWN UNIVERSITY   (United States)

Author keywords

Apoptosis; Cancer heterogeneity; Estrogen receptor; Human breast cancer; Invasion; Mass spectrometry; Metastasis suppressor; Protein biomarker; Proteomics; Tumor progression

Indexed keywords

CALCIUM BINDING PROTEIN; CALCIUM BINDING PROTEIN A11; ESTROGEN RECEPTOR ALPHA; GALECTIN 1; NUCLEOSIDE DIPHOSPHATE KINASE A; PROTEIN S 100; RAL PROTEIN; RALA PROTEIN; RETINOIC ACID BINDING PROTEIN; RETINOIC ACID BINDING PROTEIN 1; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG; URIDINE PHOSPHORYLASE; URIDINE PHOSPHORYLASE 2;

APOPTOSIS; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER INVASION; CELL DIFFERENTIATION; CONTROLLED STUDY; DNA DAMAGE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRADUCTAL CARCINOMA; MASS SPECTROMETRY; PROTEIN EXPRESSION; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING; BREAST TUMOR; FEMALE; METABOLISM; METASTASIS; PATHOLOGY; PHENOTYPE;

BLOTTING, WESTERN; BREAST NEOPLASMS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; NEOPLASM METASTASIS; PHENOTYPE; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 77957343443     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-010-9338-8     Document Type: Article

References (64)

1. KA Skinner MJ Silverstein 2001 The management of ductal carcinoma in situ of the breast Endocr Relat Cancer 8 1 33 45 10.1677/erc.0.0080033 11350725 (Pubitemid 32520252)
2. JL Jones 2006 Overdiagnosis and overtreatment of breast cancer: progression of ductal carcinoma in situ: the pathological perspective Breast Cancer Res 8 2 204 10.1186/bcr1397 16677423
3. F Jolicoeur TA Seemayer G Gabbiani, et al. 2002 Multifocal, nascent, and invasive myoepithelial carcinoma (Malignant myoepithelioma) of the breast: an immunohistochemical and ultrastructural study Int J Surg Path 10 4 281 291 10.1177/106689690201000406
4. AG Nerlich S Haraida H Hagedorn, et al. 1995 Morphological aspects of basement-membranes and their receptors in benign and malignant neoplasms Int J Oncol 6 6 1193 1202
5. A Tsubura N Shikata T Inui, et al. 1988 Immunohistochemical localization of myoepithelial cells and basement-membrane in normal, benign and malignant human-breast lesions Virchows Archiv A Pathol Anat Histopathol 413 2 133 139 10.1007/BF00749674
6. YG Man QXA Sang 2004 The significance of focal myoepithelial cell layer disruptions in human breast tumor invasion: a paradigm shift from the "protease-centered" hypothesis Exp Cell Res 301 2 103 118 10.1016/j.yexcr.2004.08.037 15530847 (Pubitemid 39504964)
7. JA Gustafsson 1999 Estrogen receptor beta-a new dimension in estrogen mechanism of action J Endocrinol 163 3 379 383 10.1677/joe.0.1630379 10588810
8. S Green P Walter V Kumar, et al. 1986 Human estrogen-receptor cDNA-sequence, expression and homology to V-Erb-A Nature 320 6058 134 139 10.1038/320134a0 3754034
9. GL Greene P Gilna M Waterfield, et al. 1986 Sequence and expression of human estrogen-receptor complementary-DNA Science 231 4742 1150 1154 10.1126/science.3753802 3753802
10. G Kuiper E Enmark M Pelto-Huikko, et al. 1996 Cloning of a novel estrogen receptor expressed in rat prostate and ovary Proc Natl Acad Sci USA 93 12 5925 5930 10.1073/pnas.93.12.5925 8650195 (Pubitemid 26190778)
11. S Mosselman J Polman R Dijkema 1996 ER beta: identification and characterization of a novel human estrogen receptor FEBS Lett 392 1 49 53 10.1016/0014-5793(96)00782-X 8769313 (Pubitemid 26268330)
12. E Anderson R Clarke I Laidlaw, et al. 1996 Experiments on proliferation of normal human breast tissue in nude mice do not show that progesterone does not stimulate breast cells: reply Endocrinology 137 4 1505 1506 10.1210/en.137.4.1505 (Pubitemid 26095271)
13. GP Skliris K Munot SM Bell, et al. 2003 Reduced expression of oestrogen receptor beta in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model J Pathol 201 2 213 220 10.1002/path.1436 14517838 (Pubitemid 37258932)
14. A Bardin N Boulle G Lazennec, et al. 2004 Loss of ER beta expression as a common step in estrogen-dependent tumor progression Endocr Relat Cancer 11 3 537 551 10.1677/erc.1.00800 15369453 (Pubitemid 39331282)
15. BW Park KS Kim MK Heo, et al. 2003 Expression of estrogen receptor-beta in normal mammary and tumor tissues: is it protective in breast carcinogenesis? Breast Cancer Res Treat 80 1 79 85 10.1023/A:1024406223619 12889601 (Pubitemid 36851287)
16. YG Man L Tai R Barner, et al. 2003 Cell clusters overlying focally disrupted mammary myoepithelial cell layers and adjacent cells within the same duct display different immunohistochemical and genetic features: implications for tumor progression and invasion Breast Cancer Res 5 6 R231 R241 10.1186/bcr653 14580259
17. YG Man KM Shekitka GL Bratthauer, et al. 2002 Immunohistochemical and genetic alterations in mammary epithelial cells immediately overlying focally disrupted myoepithelial cell layers Breast Cancer Res Treat 76 S143 S143
18. M Yousefi R Mattu CL Gao, et al. 2005 Mammary ducts with and without focal myoepithelial cell layer disruptions show a different frequency of white blood cell infiltration and growth pattern: Implications for tumor progression and invasion Appl Immunohistochem Mol Morphol 13 1 30 37 10.1097/00129039- 200503000-00006 15722791 (Pubitemid 40283800)
19. ER Sauter W Zhu XJ Fan, et al. 2002 Proteomic analysis of nipple aspirate fluid to detect biologic markers of breast cancer Br J Cancer 86 9 1440 1443 10.1038/sj.bjc.6600285 11986778 (Pubitemid 34548067)
20. JN Li Z Zhang J Rosenzweig, et al. 2002 Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer Clin Chem 48 8 1296 1304 12142387
21. ZJ Sahab SM Semaan QXA Sang 2007 Methodology and applications of disease biomarker identification in human serum Biomark Insights 2 21 43 19662190
22. KA O'Neill FR Miller TJ Barder, et al. 2003 Profiling the progression of cancer: separation of microsomal proteins in MCF10 breast epithelial cell lines using nonporous chromatophoresis Proteomics 3 7 1256 1269 10.1002/pmic.200300446 (Pubitemid 36929547)
23. WG Wu XM Tang W Hu, et al. 2002 Identification and validation of metastasis-associated proteins in head and neck cancer cell lines by two-dimensional electrophoresis and mass spectrometry Clin Exp Metastasis 19 4 319 326 10.1023/A:1015515119300 12090472 (Pubitemid 34606757)
24. DK Ornstein JW Gillespie CP Paweletz, et al. 2000 Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines Electrophoresis 21 11 2235 2242 10.1002/1522-2683(20000601)21:11<2235:: AID-ELPS2235>3.0.CO;2-A 10892734 (Pubitemid 30435823)
25. JD Wulfkuhle DC Sgroi H Krutzsch, et al. 2002 Proteomics of human breast ductal carcinoma in situ Cancer Res 62 22 6740 6749 12438275
26. R Bischoff TM Luider 2004 Methodological advances in the discovery of protein and peptide disease markers J Chromatogr B Analyt Technol Biomed Life Sci 803 1 27 40 10.1016/j.jchromb.2003.09.004 15025996 (Pubitemid 38340636)
27. RI Somiari A Sullivan S Russell, et al. 2003 High-throughput proteomic analysis of human infiltrating ductal carcinoma of the breast Proteomics 3 10 1863 1873 10.1002/pmic.200300560 14625848 (Pubitemid 37305880)
28. SM Hanash 2000 Biomedical applications of two-dimensional electrophoresis using immobilized pH gradients: current status Electrophoresis 21 6 1202 1209 10.1002/(SICI)1522-2683(20000401)21:6<1202::AID-ELPS1202>3.0.CO;2-I 10786892 (Pubitemid 30230784)
29. ZJ Sahab Y Suh QXA Sang 2005 Isoelectric point-based prefractionation of proteins from crude biological samples prior to two-dimensional gel electrophoresis J Proteome Res 4 6 2266 2272 10.1021/pr0501822 16335975 (Pubitemid 41814296)
30. PA Binz DF Hochstrasser RD Appel 2003 Mass spectrometry-based proteomics: current status and potential use in clinical chemistry Clin Chem Lab Med 41 12 1540 1551 10.1515/CCLM.2003.237 14708878 (Pubitemid 38055005)
31. R Aebersold M Mann 2003 Mass spectrometry-based proteomics Nature 422 6928 198 207 10.1038/nature01511 12634793 (Pubitemid 36362757)
32. PL Ferguson RD Smith 2003 Proteome analysis by mass spectrometry Annu Rev Biophys Biomol Struct 32 399 424 10.1146/annurev.biophys.32.110601.141854 12574065 (Pubitemid 37056235)
33. AJR Heck J Krijgsveld 2004 Mass spectrometry-based quantitative proteomics Expert Rev Proteomics 1 3 317 326 10.1586/14789450.1.3.317 15966828
34. I Feuerstein M Rainer K Bernardo, et al. 2005 Derivatized cellulose combined with MALDI-TOF MS: a new tool for serum protein profiling J Proteome Res 4 6 2320 2326 10.1021/pr050227z 16335981 (Pubitemid 41814302)
35. ZJ Sahab KA Iczkowski QXA Sang 2007 Anion exchange fractionation of serum proteins versus albumin elimination Anal Biochem 368 1 24 32 10.1016/j.ab.2007.06.004 17618595 (Pubitemid 47058437)
36. M Karas F Hillenkamp 1988 Laser desorption ionization of proteins with molecular masses exceeding 10000 Daltons Anal Chem 60 20 2299 2301 10.1021/ac00171a028 3239801
37. K Tanaka H Waki Y Ido, et al. 1988 Protein and polymer analyses up to m/z 100,000 by laser ionization time-of-flight mass spectrometry Rapid Commun Mass Spectrom 2 8 151 153 10.1002/rcm.1290020802
38. J Schiller J Arnhold S Benard, et al. 1999 Lipid analysis by matrix-assisted laser desorption and ionization mass spectrometry: a methodological approach Anal Biochem 267 1 46 56 10.1006/abio.1998.3001 9918654 (Pubitemid 29061805)
39. MM Briehl AF Baker LM Siemankowski, et al. 1997 Modulation of antioxidant defenses during apoptosis Oncol Res 9 6-7 281 285 9406233
40. LW Oberley GR Buettner 1979 Role of superoxide-dismutase in cancer-review Cancer Res 39 4 1141 1149 217531
41. E Tchevkina L Agapova N Dyakova, et al. 2005 The small G-protein RalA stimulates metastasis of transformed cells Oncogene 24 3 329 335 10.1038/sj.onc.1208094 15467745 (Pubitemid 40188581)
42. Y Ward W Wang E Woodhouse, et al. 2001 Signal pathways which promote invasion and metastasis: critical and distinct contributions of extracellular signal-regulated kinase and Ral-specific guanine exchange factor pathways Mol Cell Biol 21 17 5958 5969 10.1128/MCB.21.17.5958-5969.2001 11486034 (Pubitemid 32737812)
43. V Jullien-Flores O Dorseuil F Romero, et al. 1995 Bridging Ral GTPase to Rho pathways. RLIP76, a Ral effector with CDC42/Rac GTPase-activating protein activity J Biol Chem 270 38 22473 22477 10.1074/jbc.270.38.22473 7673236
44. KH Lim K O'Hayer SJ Adam, et al. 2006 Divergent roles for RalA and RalB in malignant growth of human pancreatic carcinoma cells Curr Biol 16 24 2385 2394 10.1016/j.cub.2006.10.023 17174914 (Pubitemid 44894905)
45. SH Park RA Weinberg 1995 A putative effector of Ral has homology to Rho/Rac GTPase activating proteins Oncogene 11 11 2349 2355 8570186
46. CD Nobes A Hall 1995 Rho, rac, and cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia Cell 81 1 53 62 10.1016/0092-8674(95)90370-4 7536630
47. S Awasthi J Cheng SS Singhal 2000 Novel function of human RLIP76: ATP-dependent transport of glutathione conjugates and doxorubicin Biochemistry 39 31 9327 9334 10.1021/bi992964c 10924126 (Pubitemid 30626323)
48. T Sasaki Y Takai 1998 The Rho small G protein family Rho GDI system as a temporal and spatial determinant for cytoskeletal control Biochem Biophys Res Commun 245 3 641 645 10.1006/bbrc.1998.8253 9588168 (Pubitemid 28413971)
49. B Olofsson 1999 Rho guanine dissociation inhibitors: pivotal molecules in cellular signalling Cell Signal 11 8 545 554 10.1016/S0898-6568(98)00063-1 10433515 (Pubitemid 29255886)
50. G Fritz C Brachetti F Bahlmann, et al. 2002 Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters Br J Cancer 87 6 635 644 10.1038/sj.bjc.6600510 12237774
51. BL Zhang YQ Zhang MC Dagher, et al. 2005 Rho GDP dissociation inhibitor protects cancer cells against drug-induced apoptosis Cancer Res 65 14 6054 6062 10.1158/0008-5472.CAN-05-0175 16024605 (Pubitemid 40994389)
52. V Wells D Davies L Mallucci 1999 Cell cycle arrest and induction of apoptosis by beta galactoside binding protein (beta GBP) in human mammary cancer cells. A potential new approach to cancer control Eur J Cancer 35 6 978 983 10.1016/S0959-8049(99)00020-9 10533482 (Pubitemid 29277135)
53. GA Rabinovich 2005 Galectin-1 as a potential cancer target Br J Cancer 92 7 1188 1192 10.1038/sj.bjc.6602493 15785741 (Pubitemid 40604390)
54. EJ Jung HG Moon BI Cho, et al. 2007 Galectin-1 expression in cancer-associated stromal cells correlates tumor invasiveness and tumor progression in breast cancer Int J Cancer 120 11 2331 2338 10.1002/ijc.22434 17304502 (Pubitemid 46642118)
55. DL Cao RL Russell DK Zhang, et al. 2002 Uridine phosphorylase (-/-) murine embryonic stem cells clarify the key role of this enzyme in the regulation of the pyrimidine salvage pathway and in the activation of fluoropyrimidines Cancer Res 62 8 2313 2317 11956089
56. R Yan LX Wan G Pizzorno, et al. 2006 Uridine phosphorylase in breast cancer: a new prognostic factor? Front Biosci 11 2759 2766 10.2741/2005 16720348 (Pubitemid 43806577)
57. K Kawamura N Takiguchi A Wada, et al. 2006 Up-regulated expression of the uridine phosphorylase gene in human gastric tumors is correlated with a favorable prognosis Anticancer Res 26 6C 4647 4651 17214321
58. P Gorry T Lufkin A Dierich, et al. 1994 The cellular retinoic acid-binding protein-I is dispensable Proc Natl Acad Sci USA 91 19 9032 9036 10.1073/pnas.91.19.9032 8090764
59. D Dong SE Ruuska DJ Levinthal, et al. 1999 Distinct roles for cellular retinoic acid-binding proteins I and II in regulating signaling by retinoic acid J Biol Chem 274 34 23695 23698 10.1074/jbc.274.34.23695 10446126 (Pubitemid 29390288)
60. A Kondo M Sakaguchi E Makino, et al. 2002 Localization of S100C immunoreactivity in various human tissues Acta Med Okayama 56 1 31 34 11873942
61. N Oue Y Hamai Y Mitani, et al. 2004 Gene expression profile of gastric carcinoma: identification of genes and tags potentially involved in invasion, metastasis, and carcinogenesis by serial analysis of gene expression Cancer Res 64 7 2397 2405 10.1158/0008-5472.CAN-03-3514 15059891 (Pubitemid 38523892)
62. AA Memon BS Sorensen P Meldgaard, et al. 2005 Down-regulation of S100C is associated with bladder cancer progression and poor survival Clin Cancer Res 11 2 606 611 15701847
63. PS Steeg G Bevilacqua L Kopper, et al. 1988 Evidence for a novel gene associated with low tumor metastatic potential J Nat Cancer Inst 80 3 200 204 10.1093/jnci/80.3.200 3346912
64. A Leone U Flatow CR King, et al. 1991 Reduced tumor-incidence, metastatic potential, and cytokine responsiveness of Nm23-transfected melanoma-cells Cell 65 1 25 35 10.1016/0092-8674(91)90404-M 2013093